Association between tumor-infiltrating lymphocytes and oncotype DX estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 single gene scores in hormone receptor-positive/HER2-negative breast cancer.
Saved in:
| Title: | Association between tumor-infiltrating lymphocytes and oncotype DX estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 single gene scores in hormone receptor-positive/HER2-negative breast cancer. |
|---|---|
| Authors: | Ohara M; Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Mikami E; Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Inohana W; Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Kurosawa T; Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Nakame A; Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Sakakibara A; Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Ichinose Y; Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Fujimoto A; Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Nukui A; Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Asano A; Department of Breast Oncology, Saitama Medical University Hospital, Moroyama, Saitama, Japan., Shimada H; Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Asai K; Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Hirasaki M; Department of Clinical Cancer Genomics, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Yokogawa H; Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Matsuura K; Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Ishiguro H; Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Hasebe T; Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Fujiuchi N; Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Osaki A; Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Saeki T; Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan. |
| Source: | Frontiers in oncology [Front Oncol] 2026 Jan 27; Vol. 16, pp. 1677929. Date of Electronic Publication: 2026 Jan 27 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2026.1677929 |
